Myeloid and NSW Government partner on A$96m manufacturing facility dedicated to RNA immunotherapies 

Myeloid Therapeutics is building a state-of-the-art RNA manufacturing and research facility in Australia. The US company is partnering with the New South Wales Government and Macquarie University on the project.

The NSW Government is investing A$96 million in the facility. It will be the only site in Australia and one of a handful in the world where a wide range of RNA therapeutics and potential delivery technologies will be independently produced.

The facility will accelerate the commercialisation of Myeloid’s RNA-based therapeutics and enable the company to secure its supply chain for clinical development. The investment and collaboration will also enhance the growth potential of other biotechnology companies and researchers in Australia.

Speeding the development and commercialisation of RNA therapeutics

Myeloid is a clinical stage mRNA-immunotherapy company. It integrates the fields of RNA, immunology and medicine to develop novel therapies for cancer and autoimmune diseases.

The state-of-the-art RNA manufacturing and research facility will be at the Macquarie University campus in the Connect Macquarie Park Innovation District. The facility will include laboratories and other support spaces to support the development of products evaluated in Australian clinical trials and across the globe.

The facility will leverage NSW’s world-class cell and gene therapy expertise. It will also leverage the NSW RNA Production & Research Network, the UNSW RNA Institute and Australia’s first Viral Vector Manufacturing Facility at the Westmead Health and Innovation District.
   
Myeloid’s CEO and co-founder Dr. Daniel Getts is an Australian researcher.

‘By enabling control of our manufacturing processes, combined with our proven bioengineering capabilities and mRNA expertise, we have secured a unique, non-dilutive path to delivering our product portfolio to patients,’ he says.

‘We are proud to partner with NSW, who have demonstrated foresight and a willingness to innovate, by deploying capital for the facility and more broadly, for the health benefit of its citizens. We and NSW share the goal to bring innovative, cost-effective immunotherapies to patients who need them in a timely manner and on a consistent basis.’
   
Find out more about Australia’s thriving health and life sciences sector.

How Austrade helped

Austrade has supported Myeloid since May 2022. Austrade’s advice and introductions ensured Myeloid secured the best location and partners for its investment.

Austrade has:

• introduced Myeloid to Australian state governments to discuss opportunities
• invited Myeloid to various conferences and industry events where the company could meet Australian industry and build its network
• facilitated meetings with potential partners including medical research institutes and pharmaceutical companies
• arranged introductions to potential co-investors and financial sector leaders
• advised on Australian Government funding including the Medical Research Future Fund and Cooperative Research Centre grants
• invited Myeloid to join Austrade’s BIO23 delegation, where the company participated in panel discussions and attended Austrade’s investment roundtable.